阿扎胞苷杂质45 | 18531-23-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 阿扎胞苷杂质45
• 英文名称: 5'-O-acetylcytidine
• 英文别名: O^5'-acetyl-cytidine；5'-O-Acetyl-cytidin；[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl acetate
• CAS: 18531-23-2
• 化学式: C₁₁H₁₅N₃O₆
• 分子量: 285.257
• InChiKey: MEGJUQPFTKBELR-PEBGCTIMSA-N

物化性质

• 沸点：
  524.9±60.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5'-O-Acetyl-2',3'-O-isopropylidencytidin 在 montmorillonite K-10 作用下， 以 甲醇 为溶剂， 反应 10.0h， 以72%的产率得到阿扎胞苷杂质45
  参考文献：
  名称：

  粘土介导的 5'-O-乙酰基-2',3'-异亚丙基/环己基核苷的选择性水解

  摘要：

  摘要 用固体催化剂蒙脱石 K-10 在回流甲醇中选择性水解 5'-O-乙酰基-2',3'-异亚丙基/亚环己基核苷以提供 5'-O-乙酰基核苷的通用程序是描述。

  DOI：

  10.1080/00397910600639968

文献信息

• Enzymes in organic synthesis: use of subtilisin and a highly stable mutant derived from multiple site-specific mutations
  作者：Chi Huey Wong、S. T. Chen、William J. Hennen、Jeffrey A. Bibbs、Y. F. Wang、Jennifer L. C. Liu、Michael W. Pantoliano、Marc Whitlow、Philip N. Bryan

  DOI：10.1021/ja00159a006

  日期：1990.1

  wild-type enzyme to organic synthesis has been demonstrated in the regioselective acylation of nucleosides in anhydrous dimethylformamide (with 65-100% regioselectivity at the 5'-position), in the enantioselective hydrolysis of N-protected and unprotected common and uncommon amino acid esters inmore » water (with 85-98% enantioselectivity for the L-isomer), and in the synthesis of di- and oligopeptides

  发现通过六个位点特异性突变（Met50Phe、Gly169Ala、Asn76Asp、Gln206Cys、Tyr2l7Lys 和 Asn2l8Ser）衍生自枯草杆菌蛋白酶 BPN' 的枯草杆菌蛋白酶突变体（枯草杆菌蛋白酶 8350）在水溶液中比野生溶液中的稳定性高 100 倍在无水二甲基甲酰胺中比野生型稳定 50 倍。使用酯、硫酯和酰胺底物以及过渡态类似物抑制剂 Boc-Ala-Val-Phe-CFsub 3} 的动力学研究表明，野生型和突变型酶具有非常相似的特异性和催化作用特性。野生型酶的抑制常数 (Ki = 5.0 mu}M) 是突变酶 (Ki = 1.1 mu}M) 的约 5 倍，表明突变酶与反应过渡态的结合比野生型酶。该结果与观察到的相应酯和酰胺底物的速率常数一致；即，突变体的 ksub cat}/Ksub m} 值大于野生型酶的值。突变酶和野生型酶在有机合成中的应用已在无
• SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20190002906A1

  公开（公告）日：2019-01-03

  This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.

  这项发明提供了可表达的多核苷酸，可以表达目标蛋白质或多肽。用于产生蛋白质或多肽的合成mRNA构建物可以包含一个或多个5' UTR，其中5' UTR可以由植物的基因表达。在某些实施例中，5' UTR可以由拟南芥属植物的基因表达。这些合成mRNA构建物可以用作体内表达目标蛋白质或多肽的药用剂。
• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：——

  公开号：US20030087873A1

  公开（公告）日：2003-05-08

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  该公开的发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖有关的病况的组合物和方法，适用于宿主，包括动物，尤其是人类，使用通用式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。该发明还提供了一种有效的过程，用于量化病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，使用实时聚合酶链反应（RT-PCR）。此外，该发明揭示了可以与样本中存在的病毒数量成比例发光的探针分子。
• [EN] NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE<br/>[FR] ARN À NUCLÉOSIDE MODIFIÉ DESTINÉ À INDUIRE UNE RÉPONSE IMMUNITAIRE ADAPTATIVE
  申请人：UNIV PENNSYLVANIA

  公开号：WO2016176330A1

  公开（公告）日：2016-11-03

  The present invention relates to compositions and methods for inducing adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

  本发明涉及诱导受试者中的适应性免疫应答的组合物和方法。在某些实施例中，本发明提供一种包含编码抗原、佐剂或二者组合的核苷酸修饰核酸分子的组合物。例如，在某些实施例中，该组合物包括一种疫苗，其中包含编码抗原、佐剂或二者组合的核苷酸修饰核酸分子。
• Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
  申请人：——

  公开号：US20020015691A1

  公开（公告）日：2002-02-07

  E 1a-3a are independently selected from the group consisting of hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy, C 1-6 heteroalkoxy, 1 wherein B 1 is a leaving group, OH, a residue of a hydroxyl-containing moiety or a residue of an amine-containing moiety or 2 wherein E 6 is independently selected from the same group which defines 3 wherein E 1b-3b are independently selected from the group consisting of hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy, C 1-6 heteroalkoxy, 4 wherein B 2 is a leaving group, OH, a residue of a hydroxyl-containing moiety or a residue of an amine-containing moiety; G is a polymeric residue; Y 1-3, Y 2a-d and Y 3a-d are each independently O, S or NR 11a M 1-4 , M 2a-2d , M 3a-3d , and M 4a-4d are each independently O, S or NR 11b ; M 5 and M 5a-d are each independently X or Q, wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y 3 ) or C(═Y 3a-d ); R 1-10 , R 1a-11a , R 1b-11b , R 1c-10c and R 1d-10d are each independently selected from the group consisting of hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy; and a, b, c, d1-d6, e1-e6, f1-f6, g1-g6, h1-h6, i1-i6, j1-j6, k1-k6, l1-l6, m1-m6 are each independently zero or a positive integer.

  E1a-3a分别独立选自氢、C1-6烷基、C3-12支链烷基、C3-8环烷基、C1-6取代烷基、C3-8取代环烷基、芳基、取代芳基、芳基烷基、C1-6杂原子烷基、取代的C1-6杂原子烷基、C1-6烷氧基、苯氧基、C1-6杂原子烷氧基；其中B1是一个脱离基团、OH、含羟基团的残基或含胺基团的残基；E6独立选自定义3的相同组中；E1b-3b独立选自氢、C1-6烷基、C3-12支链烷基、C3-8环烷基、C1-6取代烷基、C3-8取代环烷基、芳基、取代芳基、芳基烷基、C1-6杂原子烷基、取代的C1-6杂原子烷基、C1-6烷氧基、苯氧基、C1-6杂原子烷氧基；其中B2是一个脱离基团、OH、含羟基团的残基或含胺基团的残基；G是聚合物残基；Y1-3、Y2a-d和Y3a-d分别独立为O、S或NR11a；M1-4、M2a-2d、M3a-3d和M4a-4d分别独立为O、S或NR11b；M5和M5a-d分别独立为X或Q，其中X是一个电子吸引基团，Q是一个含有自由电子对的团，其位置距离C(═Y3)或C(═Y3a-d)三到六个原子；R1-10、R1a-11a、R1b-11b、R1c-10c和R1d-10d分别独立选自氢、C1-6烷基、C3-12支链烷基、C3-8环烷基、C1-6取代烷基、C3-8取代环烷基、芳基、取代芳基、芳基烷基、C1-6杂原子烷基、取代的C1-6杂原子烷基、C1-6烷氧基、苯氧基和C1-6杂原子烷氧基；a、b、c、d1-d6、e1-E6、f1-f6、g1-g6、h1-h6、i1-i6、j1-j6、k1-k6、l1-l6、m1-m6分别独立为零或正整数。